Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Mehmet Erdem Cakmak, Nida Öztop, Osman Ozan Yeğit & Özlem Özdedeoğlu. (2023) Evaluation of the clinical features and laboratory data of patients with severe asthma classified as super-responder or non super-responder to omalizumab treatment: a single-center real-life study. Journal of Asthma 60:10, pages 1862-1868.
Read now
Read now
Yaqin Li, Xiaoyan Li, Biyu Zhang, Qing Yu & Yanming Lu. (2022) Predictive biomarkers for response to omalizumab in patients with severe allergic asthma: a meta-analysis. Expert Review of Respiratory Medicine 16:9, pages 1023-1033.
Read now
Read now
Charlene M Prazma, Marco Idzko, Jo Anne Douglass, Arnaud Bourdin, Stephen Mallett, Frank C Albers & Steven W Yancey. (2021) Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes. Journal of Asthma and Allergy 14, pages 675-683.
Read now
Read now
Sheila Cabrejos, Ana Moreira, Andreina Ramirez, Santiago Quirce, Gregorio Soto Campos, Ignacio Dávila & Paloma Campo. (2020) FENOMA Study: Achieving Full Control in Patients with Severe Allergic Asthma. Journal of Asthma and Allergy 13, pages 159-166.
Read now
Read now
Cristoforo Incorvaia, Marina Mauro, Elena Makri, Gualtiero Leo & Erminia Ridolo. (2018) Two decades with omalizumab: what we still have to learn. Biologics: Targets and Therapy 12, pages 135-142.
Read now
Read now
Articles from other publishers (30)
Susana Rojo-Tolosa, José Antonio Sánchez-Martínez, Laura Elena Pineda-Lancheros, José María Gálvez-Navas, María Victoria González-Gutiérrez, Gonzalo Jiménez-Gálvez, Cristina Pérez-Ramírez, Concepción Morales-García & Alberto Jiménez-Morales. (2023) Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype. International Journal of Molecular Sciences 24:8, pages 7029.
Crossref
Crossref
Mikhail A. Kharitonov, Yulia S. Burkova, Vladimir V. Salukhov & Anastasia S. Sapronova. (2022) Some features of the coronavirus infection course in bronchial asthma patients. Bulletin of the Russian Military Medical Academy 24:3, pages 537-546.
Crossref
Crossref
Chenda Chheang, Stéphane Guinand, Christophe Von Garnier & Claudio Sartori. (2022) New perspectives of biological therapy for severe asthma in adults and adolescents. Swiss Medical Weekly 152:2122, pages w30176.
Crossref
Crossref
Hitasha Rupani, Jessica Gates, Joanne E. Kavanagh & David J. Jackson. 2022. Eosinophilic Lung Diseases. Eosinophilic Lung Diseases
73
99
.
Mitsuru Tsuge, Masanori Ikeda, Yoichi Kondo & Hirokazu Tsukahara. (2022) Severe pediatric asthma with a poor response to omalizumab: a report of three cases and three-dimensional bronchial wall analysis. Journal of International Medical Research 50:1, pages 030006052110704.
Crossref
Crossref
Silvano Dragonieri & Giovanna Elisiana Carpagnano. (2021) Biological therapy for severe asthma. Asthma Research and Practice 7:1.
Crossref
Crossref
Joanne E. Kavanagh, Andrew P. Hearn & David J. Jackson. (2022) A pragmatic guide to choosing biologic therapies in severe asthma. Breathe 17:4, pages 210144.
Crossref
Crossref
Claus Bachert, Marcus Maurer, Oscar Palomares & William W. Busse. (2021) What is the contribution of IgE to nasal polyposis?. Journal of Allergy and Clinical Immunology 147:6, pages 1997-2008.
Crossref
Crossref
Francesco Menzella, Giulia Ghidoni, Carla Galeone, Silvia Capobelli, Chiara Scelfo & Nicola Cosimo Facciolongo. (2021) Immunological Aspects Related to Viral Infections in Severe Asthma and the Role of Omalizumab. Biomedicines 9:4, pages 348.
Crossref
Crossref
Riccardo Castagnoli, Maria De Filippo, Martina Votto, Alessia Marseglia, Lorenza Montagna, Gian Luigi Marseglia & Amelia Licari. (2020) An update on biological therapies for pediatric allergic diseases. Minerva Pediatrica 72:5.
Crossref
Crossref
Carlo Cavaliere, Elona Begvarfaj, Cristoforo Incorvaia, Bruno Sposato, Marco Brunori, Andrea Ciofalo, Antonio Greco, Marco de Vincentiis & Simonetta Masieri. (2020) Long-term omalizumab efficacy in allergic rhinitis. Immunology Letters 227, pages 81-87.
Crossref
Crossref
Marco Caminati, Diego Bagnasco, Lanny J. Rosenwasser, Andrea Vianello & Gianenrico Senna. (2020) Biologics for the Treatments of Allergic Conditions. Immunology and Allergy Clinics of North America 40:4, pages 549-564.
Crossref
Crossref
C. Braun, M. Vocanson, J.F. Nicolas & A. Nosbaum. (2020) Physiopathologie de la dermatite atopique et des autres maladies atopiques : une approche globale est-elle possible ?. Annales de Dermatologie et de Vénéréologie 147:11, pages 11S4-11S11.
Crossref
Crossref
Andrew P. Hearn, Brian D. Kent & David J. Jackson. (2020) Biologic treatment options for severe asthma. Current Opinion in Immunology 66, pages 151-160.
Crossref
Crossref
I. S. Krysanov, V. S. Krysanova, O. I. Karpov & V. Yu. Ermakova. (2020) Influence of dupilumab on the economic burden of severe asthma and atopic dermatitis. Kachestvennaya klinicheskaya praktika:3, pages 15-26.
Crossref
Crossref
Arash R. Safavi & Michael P. Platt. (2020) Biologic Therapeutics and Their Role in Allergic Disease of the Unified Airway. Current Otorhinolaryngology Reports 8:2, pages 185-190.
Crossref
Crossref
Paloma Campo, Gregorio Soto Campos, Marina Blanco Aparicio, Ana Moreira Jorge, Héctor Manuel González Expósito, Santiago Quirce & Ignacio Dávila. (2019) Severe asthma phenotypes in patients controlled with omalizumab: A real-world study. Respiratory Medicine 159, pages 105804.
Crossref
Crossref
Abhishek Kavati, Maryia Zhdanava, Benjamin Ortiz, Jason Lecocq, Bradd Schiffman, Dominic Pilon, Harriet Ho, Patrick Lefebvre & Brian Stone. (2019) Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma. Clinical Therapeutics 41:10, pages 1956-1971.
Crossref
Crossref
Li-chun Tian, Qing-qing Zhu, Jun Li, Ai-jie Liu & Guang-rui Huang. (2019) Aerosol Inhalation-mediated Delivery of an Adeno-associated Virus 5-expressed Antagonistic Interleukin-4 Mutant Ameliorates Experimental Murine Asthma. Archives of Medical Research 50:6, pages 384-392.
Crossref
Crossref
Marc Humbert, Frank C. Albers, Daniel J. Bratton, Steven W. Yancey, Mark C. Liu, Soichiro Hozawa, Jean-Pierre Llanos & Namhee Kwon. (2019) Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility. Respiratory Medicine 154, pages 69-75.
Crossref
Crossref
Erika Méndez-Enríquez & Jenny Hallgren. (2019) Mast Cells and Their Progenitors in Allergic Asthma. Frontiers in Immunology 10.
Crossref
Crossref
Bruno Sposato, Marco Scalese, Manlio Milanese, Simonetta Masieri, Carlo Cavaliere, Manuela Latorre, Nicola Scichilone, Alberto Ricci, Alberto Cresti, Pierachille Santus, Carmela Olivieri, Antonio Perrella, Paola Rogliani, Pierluigi Paggiaro, B. Sposato, M.G. Migliorini, M. Di Tomassi, C. Olivieri, A. Perrella, G. Camiciottoli, R. Maselli, G. Pelaia, M.T. Busceti, E. Sabato, M.G. Cagnazzo, F. Colombo, L. Palumbo, A. Ravazzi, C. Bucca, M.F. Caiaffa, A. Berra, C. Calabrese, A.A. Stanziola, P. Schino, M. Di Gioacchino, P. Rogliani, M. Cazzola, A. Segreti, E.A. Pastorello, G. Scibilia, A. Vianello, M.R. Marchi, L. Paladini, S. Baglioni, M. Abbritti, F. Almerigogna, A. Matucci, A. Vultaggio, E. Maggi, P. Maestrelli, G. Guarnieri, G. Steinhilber, M. Bonavia, P. Rottoli, E. Bargagli, G. Senna, M. Caminati, L. Macchia, V. Bellia, N. Scichilone, P. Paggiaro, F. Novelli, M. Latorre, L. Vergura, S. Masieri, M. Scalese, Y. Rosati, M. Milanese, I. Folletti, R. Pio, A. Pio, U. Maccari, C. Maggiorelli, R. Scala, L. Vignale, N. Pulerà, G.E. Carpagnano & M.P. Foschino Barbaro. (2019) Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes. The Journal of Allergy and Clinical Immunology: In Practice 7:5, pages 1643-1646.
Crossref
Crossref
Qi HuangLele HanRong LvLing Ling. (2019) Magnolol exerts anti-asthmatic effects by regulating Janus kinase-signal transduction and activation of transcription and Notch signaling pathways and modulating Th1/Th2/Th17 cytokines in ovalbumin-sensitized asthmatic mice. The Korean Journal of Physiology & Pharmacology 23:4, pages 251.
Crossref
Crossref
Ioana Sorina Morariu, Bogdan A. Stana, Alice Azoicăi & Evelina Moraru. (2019) Moderate-persistent asthma in children – omalizumab benefits. Case presentation. Pediatru.ro 1:53, pages 46.
Crossref
Crossref
Farnaz Tabatabaian. 2019. Allergy and Asthma. Allergy and Asthma
275
288
.
Laércia K. D. Paiva Ferreira, Larissa A. M. Paiva Ferreira, Adriano Francisco Alves, Fagner Carvalho Leite, Luiz A. de Araújo Silva, Giciane Carvalho Vieira, Luís Cezar Rodrigues & Marcia Regina Piuvezam. (2018) MHTP, 2-Methoxy-4-(7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl) phenol, a Synthetic Alkaloid, Induces IFN-γ Production in Murine Model of Ovalbumin-Induced Pulmonary Allergic Inflammation. Inflammation 41:6, pages 2116-2128.
Crossref
Crossref
Samuel N. Uwaezuoke, Adaeze C. Ayuk, Joy N. Eze & Sandra K. Owusu. (2018) Asthma in Childhood: Current Perspectives on Diagnosis and Treatment. EMJ Respiratory, pages 90-99.
Crossref
Crossref
Corrado Pelaia, Cecilia Calabrese, Rosa Terracciano, Francesco de Blasio, Alessandro Vatrella & Girolamo Pelaia. (2018) Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness. Therapeutic Advances in Respiratory Disease 12, pages 175346661881019.
Crossref
Crossref
Rosalia Emma, Jaymin B. Morjaria, Virginia Fuochi, Riccardo Polosa & Massimo Caruso. (2018) Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Therapeutic Advances in Respiratory Disease 12, pages 175346661880849.
Crossref
Crossref
Farnaz Tabatabaian. 2019. Allergy and Asthma. Allergy and Asthma
1
14
.